174 related articles for article (PubMed ID: 15209404)
1. Trials, tribulations, and trends in tumor modeling in mice.
Schuh JC
Toxicol Pathol; 2004; 32 Suppl 1():53-66. PubMed ID: 15209404
[TBL] [Abstract][Full Text] [Related]
2. Testing therapeutic potency of anticancer drugs in animal studies: a commentary.
Den Otter W; Steerenberg PA; Van der Laan JW
Regul Toxicol Pharmacol; 2002 Apr; 35(2 Pt 1):266-72. PubMed ID: 12052010
[TBL] [Abstract][Full Text] [Related]
3. The mighty mouse: genetically engineered mouse models in cancer drug development.
Sharpless NE; Depinho RA
Nat Rev Drug Discov; 2006 Sep; 5(9):741-54. PubMed ID: 16915232
[TBL] [Abstract][Full Text] [Related]
4. Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
Hoffman RM
Methods Mol Med; 2005; 111():297-322. PubMed ID: 15911987
[TBL] [Abstract][Full Text] [Related]
5. Practices and pitfalls of mouse cancer models in drug discovery.
Kung AL
Adv Cancer Res; 2007; 96():191-212. PubMed ID: 17161681
[TBL] [Abstract][Full Text] [Related]
6. Genetically engineered models have advantages over xenografts for preclinical studies.
Becher OJ; Holland EC
Cancer Res; 2006 Apr; 66(7):3355-8, discussion 3358-9. PubMed ID: 16585152
[TBL] [Abstract][Full Text] [Related]
7. From mice to men: GEMMs as trial patients for new NSCLC therapies.
Hayes SA; Hudson AL; Clarke SJ; Molloy MP; Howell VM
Semin Cell Dev Biol; 2014 Mar; 27():118-27. PubMed ID: 24718320
[TBL] [Abstract][Full Text] [Related]
8. In vitro assays of chemotherapeutic sensitivity.
Carney DN; Winkler CF
Important Adv Oncol; 1985; ():78-103. PubMed ID: 3916747
[TBL] [Abstract][Full Text] [Related]
9. Medicine. Building better mouse models for studying cancer.
Marx J
Science; 2003 Mar; 299(5615):1972-5. PubMed ID: 12663895
[No Abstract] [Full Text] [Related]
10. Orthotopic models are necessary to predict therapy of transplantable tumors in mice.
Killion JJ; Radinsky R; Fidler IJ
Cancer Metastasis Rev; 1998-1999; 17(3):279-84. PubMed ID: 10352881
[TBL] [Abstract][Full Text] [Related]
11. [New approaches in experimental cancerology: in search of therapeutic models].
Guilbaud N; Kraus-Berthier L; Meyer-Losic F; Pierré A; Hickman J
Bull Cancer; 2001 Jan; 88(1):75-84. PubMed ID: 11182656
[No Abstract] [Full Text] [Related]
12. Chemoinformatic analysis of NCI preclinical tumor data: evaluating compound efficacy from mouse xenograft data, NCI-60 screening data, and compound descriptors.
Wallqvist A; Huang R; Covell DG
J Chem Inf Model; 2007; 47(4):1414-27. PubMed ID: 17555311
[TBL] [Abstract][Full Text] [Related]
13. Overview of genetically engineered mouse models of colorectal carcinoma to enable translational biology and drug development.
Roper J; Martin ES; Hung KE
Curr Protoc Pharmacol; 2014 Jun; 65():14.29.1-10. PubMed ID: 24934606
[TBL] [Abstract][Full Text] [Related]
14. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development.
Peterson JK; Houghton PJ
Eur J Cancer; 2004 Apr; 40(6):837-44. PubMed ID: 15120039
[TBL] [Abstract][Full Text] [Related]
15. Modeling therapy resistance in genetically engineered mouse cancer models.
Rottenberg S; Jonkers J
Drug Resist Updat; 2008; 11(1-2):51-60. PubMed ID: 18165147
[TBL] [Abstract][Full Text] [Related]
16. Clinical studies on a new screening assay for anticancer agents using nude mice and isotopic evaluation.
Noso Y; Niimi K; Nishiyama M; Hirabayashi N; Toge T; Niimoto M; Hattori T
Cancer Res; 1987 Dec; 47(23):6418-22. PubMed ID: 3677085
[TBL] [Abstract][Full Text] [Related]
17. Preclinical in vitro models from genetically engineered mice for breast and colon cancer (Review).
Telang N; Katdare M
Oncol Rep; 2011 May; 25(5):1195-201. PubMed ID: 21399881
[TBL] [Abstract][Full Text] [Related]
18. What is the optimal rodent model for anti-tumor drug testing?
Kerbel RS
Cancer Metastasis Rev; 1998-1999; 17(3):301-4. PubMed ID: 10352884
[TBL] [Abstract][Full Text] [Related]
19. In vivo/ex vivo and in situ assays used in cancer research: a brief review.
Teicher BA
Toxicol Pathol; 2009 Jan; 37(1):114-22. PubMed ID: 19098118
[TBL] [Abstract][Full Text] [Related]
20. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.
Kerbel RS; Guerin E; Francia G; Xu P; Lee CR; Ebos JM; Man S
Breast; 2013 Aug; 22 Suppl 2():S57-65. PubMed ID: 24074794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
